Ahmed Glaucoma Valve in Refractory Glaucoma: A Retrospective Study
Published: April 1, 2018 | DOI: https://doi.org/10.7860/JCDR/2018/32447.11435
Suresh Kumar, Sahil Thakur, Madhu Sharma
1. Professor, Department of Ophthalmology, Government Medical College and Hospital, Sector 32, Chandigarh, India.
2. Junior Resident, Department of Ophthalmology, Government Medical College and Hospital, Sector 32, Chandigarh, India.
3. Senior Resident, Department of Ophthalmology, Government Medical College and Hospital, Sector 32, Chandigarh, India.
Correspondence
Dr. Suresh Kumar,
Professor, Department of Ophthalmology, Government Medical College and Hospital, Sector 32, Chandigarh-160030, India.
E-mail: drsuresh.kumar.gupta@gmail.com
Introduction: Ahmed Glaucoma Valve (AGV) is a modality to surgically manage patients of glaucoma who are refractory to conventional intraocular pressure lowering drugs.
Aim: To evaluate the success rate and safety profile of AVG in patients of refractory glaucoma.
Materials and Methods: This study is a retrospective review of 30 eyes with refractory glaucoma that were implanted AGV over a period from January 2012 to November 2014. The collected data was analysed using SPSS Version 21.0, ANOVA and Kaplan-Meier survival analysis to evaluate surgical success and rate of complications.
Results: The AGV reduced the preoperative mean Intraocular Pressure (IOP) of 33.47±6.19 mmHg to 12.36±3.55 mmHg at last follow up after surgery (p-value=0.001). The dependency on anti-glaucoma drugs decreased from 2.43±1.1 to 1.1±0.5 at the last follow up visit (p-value=0.65). AGV implantation was successful in 90% eyes at 12 months (n=30), 86.7% at 24 months (n=26) and 70% eyes at 36 months (n=21). Complications requiring intervention were found in seven (23.33%) eyes.
Conclusion: Ahmed Glaucoma Valve is a reliable and safe alternative for IOP control in patients with refractory glaucoma.
[
FULL TEXT ] | [ PDF]